Pooled hazard ratios (HRs) and risk ratios (RRs) for progression-free survival (PFS), overall survival (OS), objective response rates (ORR), treatment-related adverse events (TRAEs), and discontinuation rates were obtained. Methods: We performed a systematic review and finally included eleven first-line randomized controlled trials to compare efficacy and safety outcomes among first-line IO treatment strategies versus standard platinum-based chemotherapy (CT) according to PD-L1 expression level (<1%, 1–49%, ≥50%). However, establishing the optimal therapeutic options among programmed death-ligand 1 (PD-L1) selected subgroups still addresses an unmet need in the clinical setting. *These authors are equal co-last authors.īackground: The advent of immuno-oncology (IO) represented a breakthrough in non-small cell lung cancer (NSCLC) therapy over the last few years. #These authors contributed equally to this work. Interviews with Outstanding Guest Editorsįrancesco Passiglia 1#, Antonio Galvano 2#, Valerio Gristina 2#, Nadia Barraco 2, Marta Castiglia 2, Alessandro Perez 2, Maria La Mantia 2, Antonio Russo 2*, Viviana Bazan 3*ġ Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Orbassano, Turin, Italy 2 Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 3 Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo, ItalyĬontributions: (I) Conception and design: F Passiglia, A Galvano, V Gristina (II) Administrative support: V Bazan, A Russo (III) Provision of study materials or patients: N Barraco, A Perez, M Castiglia, M La Mantia (IV) Collection and assembly of data: F Passiglia, A Galvano, V Gristina (V) Data analysis and interpretation: F Passiglia, A Galvano, V Gristina, A Russo (VI) Manuscript writing: All authors (VII) Final approval of manuscript: All authors.Policy of Dealing with Allegations of Research Misconduct.Policy of Screening for Plagiarism Process.

Checkmate 9la asco 2021